The goals of this core are to provide all projects and the other cores with centralized leadership, administrative. Cord Blood Bank and clinical research support. The Administrative component will be responsible for integrating all components of the program project grant (PO1) and overseeing progress, so that the research objectives are being met. It will provide assistance to each project and core leader with budgetary issues and will oversee the overall fiscal and budgetary management of the program. This Core will also coordinate oversight of the PO1 by convening meetings of the Internal and External Advisory Boards and implementing their recommendations. The goals of the clinical research component of this core are to provide all projects with clinical trial support in collaboration with Core B and provide an infrastructure of personnel and services that will adequately support such research. Core services will be provided in regulatory affairs, study coordination, quality assurance and control and data safety monitoring. The Regulatory Affairs component collaborates with investigators to develop and submit all required regulatory documents, including submissions to the IRB, IBC, FDA, and NIH/OBA and annual reports. This core has extensive experience with IND submission and currently supports over 45 IND studies. The Quality Control program will ensure that standard operating procedures for protocol development, conduct of clinical trials, data collection and management of clinical trials are accurately defined and being followed. The Quality Assurance program will undertake audits after the first patient is enrolled on a study and then randomly to ensure that the studies are being conducted according to Good Clinical Practices. The MD Anderson Cord Blood Bank is committed to providing cord blood units for pre-clinical peer-reviewed research to advance the field of cord blood transplantation, and will provide all the cord blood units needed to execute the studies proposed in the projects. In this PO1 we have developed strategic approaches to overcome the limitations of cord blood transplantation and will rely on testing potential solutions in carefully designed preclinical models and then translating the results to the clinic.

Public Health Relevance

Cord Blood has emerged as an important source of stem cells for patients lacking HLA-matched donors. However, the major disadvantage of cord blood is the low stem and progenitor cell dose resulting in delayed engraftment and immune reconstitution. In this P01 we have developed strategic approaches to overcome the limitations of cord blood transplantation. This Core will provide cord blood units, administrative and clinical research support to achieve the goals of this PO1.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Kellner, Joshua; Li, Sufang; Zweidler-McKay, Patrick A et al. (2015) Phenotypic and functional comparison of mobilized peripheral blood versus umbilical cord blood megakaryocyte populations. Cytotherapy 17:418-27
Deniger, Drew C; Maiti, Sourindra N; Mi, Tiejuan et al. (2014) Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 20:5708-19
Parmar, Simrit; Liu, Xiaoying; Tung, Shawndeep S et al. (2014) Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16:90-100
Kumaresan, Pappanaicken R; Manuri, Pallavi R; Albert, Nathaniel D et al. (2014) Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111:10660-5
Hildebrandt, Martin; Peggs, Karl; Uharek, Lutz et al. (2014) Immunotherapy: opportunities, risks and future perspectives. Cytotherapy 16:S120-9
Mehta, Rohtesh S; Di Stasi, Antonio; Andersson, Borje S et al. (2014) The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk 14:e1-5
Hanley, Patrick J; Bollard, Catherine M (2014) Controlling cytomegalovirus: helping the immune system take the lead. Viruses 6:2242-58
Bear, Adham S; Hanley, Patrick J; Bosque, Doyle M et al. (2014) Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy 16:1153-7
Saglio, Francesco; Hanley, Patrick J; Bollard, Catherine M (2014) The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 16:149-59
Robinson, Simon N; Thomas, Michael W; Simmons, Paul J et al. (2014) Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 16:84-9

Showing the most recent 10 out of 19 publications